Phase I clinical trials are currently underway in PDAC (NCT03611556), breast cancer (NCT03742102), and many other solid tumors (NCT03454451) to evaluate the safety and efficacy of CD73 blockade in combination with PD1 axis inhibitors (anti-PD1, anti-PDL1) (151). The gene discussed is PDCD1; the disease is breast carcinoma.